Navigation Links
Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
Date:4/20/2011

CAMBRIDGE, Mass., April 20, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

MM-111 is a bi-specific antibody that targets tumor cells over-expressing ErbB2/HER2. MM-111 is designed to inhibit the signaling between ErbB2/HER2 and ErbB3/HER3 thus disabling downstream signaling, including the phosphatidylinositol 3-kinase (PI3K) pathway, and preventing tumor proliferation. In this study, Merrimack is evaluating whether MM-111 could be safely added to standard therapies used to treat HER2 positive cancers. The study could also provide preliminary evidence of activity in patients with advanced/metastatic HER2 positive disease, an area of high unmet medical need for which there are limited treatment options.

"HER2 positive cancers are historically more aggressive and carry a poorer prognosis than other types of solid tumors," says Clet Niyikiza, Ph.D., Executive Vice President of Development, Merrimack Pharmaceuticals. "Patients with HER2 positive metastatic cancer eventually progress or are intolerant of current approved regimens. Close to half of the patients treated with such regimens fail to respond."

The Phase 1 study will evaluate the human safety and pharmacokinetics of MM-111 when administered in combination with either 1) cisplatin, capecitabine, and trastuzumab; 2) lapatinib and trastuzumab; or 3) paclitaxel and trastuzumab in patients with HER2 positive solid tumors. The study is being run in collaboration with US Oncology, a leading integrated oncology company that is affiliated with more than 1,400 physicians nationwide.

"Because ErbB3 activation has been indicated as a cause of resistance to current HER2 targeted treatments and chemotherapies, we pl
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
2. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
3. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
4. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
5. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
7. Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering
8. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
9. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
10. Bexion Pharmaceuticals Receives Outstanding Biotech Innovation Award
11. Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... April 24, 2015 Hi-Tech Pharmaceuticals refutes ... not the product of reliable scientific principles and ... basis for allegations of adulteration. The FDA is ... false premise, or misguided hope, that Methylphenylethylamine is ... are contradicted by multiple other studies and cannot ...
(Date:4/24/2015)... -- Elekta has CE marked the latest version (v5.10) of ... European clinics to deliver a sophisticated radiation therapy planning ... planning, IMRT, VMAT and stereotactic planning – all in ... ® v5.10 provides significant planning and ... 3D planning as well as the addition of MRI ...
(Date:4/23/2015)... 2015  ResMed Inc. (NYSE: RMD ) today ... Revenue for the quarter was $422.5 million, a 6 ... 2014 (a 13 percent increase on a constant currency ... 1 percent compared to the quarter ended March 31, ... $0.64, an increase of 2 percent compared to the ...
Breaking Medicine Technology:Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 3Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 4Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 5Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 6Elekta CE marks for Monaco v5.10 treatment planning system 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 11ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 12ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 13
(Date:4/25/2015)... (PRWEB) April 25, 2015 Gardant ... and wellness, management and operations, and sales and ... and Exhibition scheduled to be held from April ... LeadingAge Illinois is the largest eldercare association in ... of services for older adults, including senior housing, ...
(Date:4/25/2015)... York New York (PRWEB) April 25, 2015 ... that Dr. Jerry Blaivas has been chosen by the New ... for his contributions to medicine in the field of Urology. ... the best in his speciality, Genito-Urinary diseases. He was ... specifically in the field of urology. Not only did ...
(Date:4/25/2015)... On Friday, April 17, Interstate Batteries was ... Implementation Award. This award is given to the ... RFID technology to improve its manufacturing, supply chain or ... demonstrates how RFID is delivering real value to shareholders. ... 2015 in San Diego, the RFID industries annual trade ...
(Date:4/24/2015)... April 24, 2015 Bird B Gone, the ... applications now offers a complete line of bird control solutions ... farms. , New Flu Strains Threaten Pacific, Central and Mississippi ... post , a number of highly pathogenic avian flus ... disease is often spread when wild birds enter poultry farms. ...
(Date:4/24/2015)... 24, 2015 Multi Customer Discount , ... pumping ( http://www.zeitersseptics.com/multi-customer-discount.html ) of 1000-1500 gallons in Zeiter's ... program. This does not include any Dig fees, or ... per person. If someone is part of this group ... totaling approximately 2500 gallons or more, the cost would ...
Breaking Medicine News(10 mins):Health News:Gardant Management Solutions Staff Shares Operational Expertise 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 4Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 2Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 3
... new protein that may offer fresh insights into brain function ... second prion protein called Shadoo, that exists in addition to ... Westaway, director of the Centre for Prions and Protein Folding ... believed PrP was a unique nerve protein that folded into ...
... -- A team of Mayo Clinic researchers has discovered ... of prosthetic joints, potentially leading to better treatment options ... bacteria that adhere to the prosthetic surface, was tested ... or knee joints who were having their prosthetic joints ...
... most like to forget may be the toughest to leave ... to a new study by the University of North Carolina ... television and see footage of wounded soldiers in Iraq or ... more than a newspaper headline, said the studys lead author, ...
... in Taiwan have demonstrated for the first time ... of cardiovascular risk in young adults: inflammation, oxidative ... which appeared in the second issue for August ... Care Medicine, published by the American Thoracic Society, ...
... MADISON - In what may be the first study ... circuits involved in emotional control in patients with depression, ... brains of people with clinical depression react very differently ... with negative situations. , According to the World Health ...
... is greater among kidney transplant patients and people with ... suggests the disease is associated with immune deficiency. ... South Wales in Sydney and colleagues compared the incidence ... with that of kidney transplant patients, who have suppressed ...
Cached Medicine News:Health News:New prion protein discovered by Canadian scientists may offer insight into mad cow disease 2Health News:Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints 2Health News:Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints 3Health News:The memories you want to forget are the hardest ones to lose 2Health News:Air pollution linked to cardiovascular risk indices in healthy young adults 2Health News:Clinical depression linked to abnormal emotional brain circuits 2Health News:Clinical depression linked to abnormal emotional brain circuits 3
... The USS Sports Medicine™ AnchorSew™ 3 mm is ... the USS Sports Medicine ArthroSew suturing device to ... repair device is implanted into a prepared hole ... soft tissue. The soft tissue anchors are made ...
... This type of anchor is generally utilized ... anchor directly into the bone. Unlike other anchors ... suture anchor does not have that limitation. The ... Anchor is a mallet. The 4.4mm Stainless Steel ...
... Medicine™ Ogden™ Non-Sterile Anchor is a nonabsorbable ... bone using sutures. The device is implanted ... and is used to reattach damaged soft ... (6A14V ELI) alloy which conforms to ASTM ...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Medicine Products: